ライフサイエンスコーパス: orgasm

1 rapidity of sexual arousal, and intensity of orgasm.

2 ation; and (2) of women's ability to achieve orgasm.

3 ation and difficulty or inability to achieve orgasm.

4 h to it, genital interaction, and eventually orgasm.

5 sensuality (78%) and of inability to achieve orgasm (39%) than did the ten who had not had surgery (2

6 erection, 2) maintain an erection, 3) attain orgasm, 4) dry orgasm, and 5) whether they were sexually

7 al dryness, low libido, and not experiencing orgasms after hysterectomy.

8 icipants were scanned once immediately after orgasm and once in a baseline state.

9 ished data on female sexual desire, arousal, orgasm and pain, and on medical/iatrogenic factors assoc

10 e long-term outcomes of sexual satisfaction, orgasm and patient body image is essential, however, to

11 w instruments to objectively assess arousal, orgasm and the expulsion phase of ejaculation such as fu

12 intain an erection, 3) attain orgasm, 4) dry orgasm, and 5) whether they were sexually active.

13 et an erection, maintain an erection, attain orgasm, and being sexually active in comparison with pat

14 domains of sexual function-desire, arousal, orgasm, and ejaculation-can be affected.

15 unction (including overall function, desire, orgasm, and overall ability) decreased sharply by decade

16 Erectile function, arousal, ejaculation, orgasm, and overall satisfaction domain measures improve

17 50% of women with SCIs were able to achieve orgasm, compared with 100% of able-bodied women (p = 0.0

18 e S2-S5 spinal segments were able to achieve orgasm, compared with 59% of women with other levels and

19 functioning significantly improved in women; orgasm delay, orgasm satisfaction, and overall sexual fu

20 The rates of not experiencing orgasms dropped significantly from 7.6% before hysterect

21 Three women experienced orgasm during the CSS.

22 neuro-endocrine mechanisms underlying female orgasm evolved from and are homologous to the mechanisms

23 n an erection, frequency of ejaculation, and orgasm frequency than did patients receiving placebo, wi

24 to maintain erection, ejaculation frequency, orgasm frequency, and sexual desire.

25 en CRP and sexual satisfaction and partnered orgasms frequency for those most motivated to approach r

26 erentiate between subjective descriptions of orgasm from SCI women compared with controls.

27 del of female orgasm, suggesting that female orgasm has very deep evolutionary roots among the early

28 to quantify endogenous opioid release after orgasm in man.

29 of treatment of disorders of ejaculation and orgasm in men.

30 or frequency of sexual activity and pleasure-orgasm in the Brief index of Sexual Functioning for Wome

31 in regions that showed activation during the orgasms included hypothalamic paraventricular nucleus, m

32 re discussed for sexual desire, arousal, and orgasm or ejaculation stages of sexual responding.

33 Orgasm (P = .002) and drive/relationship (P < .001) decl

34 ower sexual cognition/fantasy (P = .003) and orgasm (P = .006) in men and sexual arousal (P = .05) an

35 The ovulatory homolog model of female orgasm posits that the neuro-endocrine mechanisms underl

36 ly, we identified 2 novel predictors, namely orgasm satisfaction and sexual behavior/experience.

37 gnificantly improved in women; orgasm delay, orgasm satisfaction, and overall sexual functioning sign

38 ested, such as desire, arousal, lubrication, orgasm, satisfaction, and painless intercourse.

39 hat pharmacological agents that affect human orgasm, such as fluoxetine, should also affect ovulation

40 pports the ovulatory homolog model of female orgasm, suggesting that female orgasm has very deep evol

41 Time to orgasm was significantly increased in women with SCIs co

42 xual desire, arousal, and ability to achieve orgasm were comparable to norms established in participa

43 l erections and experienced the sensation of orgasm without ever ejaculating.